Rimonabant redux and strategies to improve the future outlook of cb1 receptor neutral-antagonist/inverse-agonist therapies

Obesity

Volumn 19, Issue 7, 2011, Pages 1325-1334

  Ward, Sara Jane ^a   Raffa, Robert B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3 (1 METHANESULFONYLAMINO 4 HEXYN 6 YL) 6A,7,10,10A TETRAHYDRO 6,6,9 TRIMETHYL 6H DIBENZO[B,D]PYRAN; 4 AMINO (4 CHLOROBENZYL) 2 METHYL 5 PHENYL 1H PYRROL 3 YL(PHENYL)METHANONE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 3 HEXYL 1H 1,2,4 TRIAZOLE; 5 [4 (4 CYANOBUT 1 YNYL)PHENYL] 1 (2,4 DICHLOROPHENYL) 4 METHYL N (1,1 DIOXO THIOMORPHOLINO) 1H PYRAZOLE 3 CARBOXAMIDE; AM 4113; AM 6545; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; DEXFENFLURAMINE; IBIPINABANT; LH 21; METFORMIN; N PIPERIDIN 1 YL 2,4 DICHLOROPHENYL 1H PYRAZOLE 3 CARBOXAMIDE; O 2050; OTENABANT; PHENTERMINE; PRAMLINTIDE; RIMONABANT; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SURINABANT; TARANABANT; TETRAHYDROLIPSTATIN; THIOAMIDE; TM 38837; UNCLASSIFIED DRUG; URB 447;

ANHEDONIA; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EMOTIONALITY; FEEDING BEHAVIOR; HUMAN; HYPERPHAGIA; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MENTAL DISEASE; NAUSEA; NONHUMAN; OBESITY; PROTEIN PROTEIN INTERACTION; REVIEW; WEIGHT REDUCTION;

ANIMALS; APPETITE DEPRESSANTS; DEXFENFLURAMINE; DRUG DESIGN; DRUG INVERSE AGONISM; ENDOCANNABINOIDS; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SEROTONIN RECEPTOR AGONISTS;

EID: 79959653392     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.69     Document Type: Review

References (112)

1. Nissen SE, Nicholls SJ, Wolski K et al.; STRADIVARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-1560. (Pubitemid 351482794)
2. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008;57:1140-1155.
3. Xie S, Furjanic MA, Ferrara JJ et al. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism-or inverse agonism-as potential obesity treatment and other therapeutic use. J Clin Pharm Ther 2007;32:209-231. (Pubitemid 46699514)
4. Simiand J, Keane M, Keane PE, Soubrié P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998;9:179-181. (Pubitemid 28186515)
5. Arnone M, Maruani J, Chaperon F et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997;132: 104-106. (Pubitemid 27303746)
6. Colombo G, Agabio R, Diaz G et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998;63:PL113-PL117.
7. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134. (Pubitemid 41653104)
8. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIOEurope study. Lancet 2005;365:1389-1397. (Pubitemid 40523733)
9. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-775. (Pubitemid 43244304)
10. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-1672. (Pubitemid 46048528)
11. Vemuri VK, Janero DR, Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 2008;93:671-686. (Pubitemid 351410420)
12. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 2008;7:961-962.
13. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid- oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009;205:171-174.
14. Lee HK, Choi EB, Pak CS. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem 2009;9:482-503.
15. Mechoulam R, Shabat SB, Hanus L et al. Endogenous cannabinoid ligands. Adv Exp Med Biol 1996;402:95-101.
16. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005;1-51.
17. Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins Leukot Essent Fatty Acids 1995;53:1-11.
18. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949. (Pubitemid 23026736)
19. Mechoulam R, Ben-Shabat S, Hanus L et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
20. Sugiura T, Kondo S, Sukagawa A et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
21. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100. (Pubitemid 43228239)
22. Fowler CJ. Oleamide: a member of the endocannabinoid family? Br J Pharmacol 2004;141:195-196. (Pubitemid 38250886)
23. Matias I, Bisogno T, Di Marzo V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 2006;30 Suppl 1:S7-S12.
24. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462. (Pubitemid 44394908)
25. Varma N, Carlson GC, Ledent C, Alger BE. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci 2001;21:RC188.
26. Kim J, Isokawa M, Ledent C, Alger BE. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci 2002;22:10182-10191. (Pubitemid 35416857)
27. Witting A, Walter L, Wacker J, Möller T, Stella N. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci USA 2004;101:3214-3219. (Pubitemid 38327760)
28. Di S, Boudaba C, Popescu IR et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. J Physiol (Lond) 2005;569: 751-760. (Pubitemid 41830220)
29. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG. Rapid glucocorticoidmediated endocannabinoid release and opposing regulation of glutamate and gammaaminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005;146:4292-4301. (Pubitemid 41324025)
30. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 2002;68:247-286. (Pubitemid 36009278)
31. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002;296:678-682.
32. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003;83:1017-1066. (Pubitemid 36828930)
33. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002; 68-69:619-631. (Pubitemid 35247425)
34. Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994;268:1612-1623. (Pubitemid 24100385)
35. Herkenham M, Lynn AB, Little MD et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990;87:1932-1936.
36. Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Front Horm Res 2008;36:135-145.
37. André A, Gonthier MP. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol 2010;42:1788-1801.
38. Rinaldi-Carmona M, Barth F, Héaulme M et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240-244. (Pubitemid 24268029)
39. Traynor K. Panel advises against rimonabant approval. Am J Health Syst Pharm 2007;64: 1460-1461. (Pubitemid 47077124)
40. Lin LS, Lanza TJ Jr, Jewell JP et al. Discovery of N-[(1S,2S)-3-(4- Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 2006;49:7584-7587. (Pubitemid 46033647)
41. Addy C, Wright H, Van Laere K et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008;7:68-78.
42. Lin LS, Ha S, Ball RG et al. Conformational analysis and receptor docking of N-[(1S,2S)- 3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl- 2-{[5-(trifluoromethyl) pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. J Med Chem 2008;51:2108-2114. (Pubitemid 351503266)
43. Fong TM, Guan XM, Marsh DJ et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)- 2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2- [[5-(trifluoromethyl)pyridin-2-yl] oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 2007;321:1013-1022. (Pubitemid 46762708)
44. Proietto J, Rissanen A, Harp JB et al. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes (Lond) 2010;34:1243-1254.
45. Aronne LJ, Tonstad S, Moreno M et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) 2010;34:919-935.
46. Griffith DA, Hadcock JR, Black SC et al. Discovery of 1-[9-(4-chlorophenyl)- 8-(2-chlorophenyl)-9H-purin-6-yl]-4- ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. J Med Chem 2009;52:234-237.
47. Hadcock JR, Griffith DA, Iredale PA et al. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity. Biochem Biophys Res Commun 2010;394:366-371.
48. Rinaldi-Carmona M, Barth F, Congy C et al. SR147778 [5-(4-bromophenyl)-1- (2,4- dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1Hpyrazole- 3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004;310:905-914. (Pubitemid 39108910)
49. Srivastava BK, Soni R, Joharapurkar A et al. Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'- [(4-chlorophenyl)- sulfonyl]-4-phenyl-4,5- dihydro-1H-pyrazole-1-caboxamidine (SLV- 319) a potent CB1 receptor antagonist by imidazole and oxazole. Bioorg Med Chem Lett 2008;18:963-968. (Pubitemid 351187882)
50. Srivastava BK, Joharapurkar A, Raval S et al. Diaryl dihydropyrazole-3- carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model. J Med Chem 2007;50: 5951-5966.
51. 7TM Pharma. 7TM Pharma successfully conducts clinical Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS. http://7tm.com/News.aspx?M=News&PID= 5&NewsID=58 Accessed 17 November 2010.
52. International Congress on Obesity. Experimental antiobesity drug shows promise in avoiding risk of psychiatric side effects displayed by the first generation product. http://www.ico2010.org/documents/Cannabinoidsrelease-final. pdf Accessed 17 November 2010.
53. Sink KS, McLaughlin PJ, Wood JA et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008;33: 946-955. (Pubitemid 351252707)
54. Tam J, Vemuri VK, Liu J et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120:2953-2966.
55. Cluny NL, Vemuri VK, Chambers AP et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010;161:629-642.
56. Randall PA, Vemuri VK, Segovia KN et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav 2010;97:179-184.
57. Chen RZ, Frassetto A, Lao JZ et al. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur J Pharmacol 2008;584: 338-342.
58. Pavon FJ, Bilbao A, Hernández-Folgado L et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- 3-hexyl-1H-1,2,4-triazole-LH 21. Neuropharmacology 2006;51:358-366. (Pubitemid 44081792)
59. LoVerme J, Duranti A, Tontini A et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett 2009;19:639-643.
60. Gardner A, Mallet PE. Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur J Pharmacol 2006;530:103-106. (Pubitemid 43037130)
61. Boström J, Olsson RI, Tholander J et al. Novel thioamide derivatives as neutral CB1 receptor antagonists. Bioorg Med Chem Lett 2010;20:479-482.
62. Cota D, Marsicano G, Tschöp M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-431. (Pubitemid 38063771)
63. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrié P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28:640-648. (Pubitemid 38491158)
64. Thornton-Jones ZD, Vickers SP, Clifton PG. The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology (Berl) 2005;179: 452-460. (Pubitemid 40569048)
65. Jbilo O, Ravinet-Trillou C, Arnone M et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:1567-1569. (Pubitemid 41279033)
66. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003;167: 103-111. (Pubitemid 36535298)
67. Osei-Hyiaman D, Liu J, Zhou L et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118:3160-3169.
68. Pério A, Rinaldi-Carmona M, Maruani J et al. Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 1996;7:65-71. (Pubitemid 26051785)
69. Quarta C, Bellocchio L, Mancini G et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 2010;11:273-285.
70. Rinaldi-Carmona M, Barth F, Héaulme M et al. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 1995;56: 1941-1947.
71. Fride E, Braun H, Matan H et al. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. Pediatr Res 2007;62:533-536. (Pubitemid 351338985)
72. Hodge J, Bow JP, Plyler KS et al. The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behav Brain Res 2008;193:298-305.
73. Chambers AP, Vemuri VK, Peng Y et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 2007;293:R2185-R2193. (Pubitemid 350224010)
74. Sink KS, Segovia KN, Sink J et al. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 2010;20:112-122.
75. Järbe TU, LeMay BJ, Olszewska T et al. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on openfield behaviors in rats. Pharmacol Biochem Behav 2008;91:84-90.
76. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 2004;65:2-11. (Pubitemid 38113879)
77. Giraldo J, Serra J, Roche D, Rovira X. Assessing receptor affinity for inverse agonists: Schild and Cheng-Prusoff methods revisited. Curr Drug Targets 2007;8:197-202. (Pubitemid 46043908)
78. Giraldo J. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue. Drug Discov Today 2010;15:411-415.
79. Poncelet M, Maruani J, Calassi R, Soubrié P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 2003;343:216-218. (Pubitemid 38365988)
80. Ward SJ, Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 2005;16:381-388. (Pubitemid 41404809)
81. McLaughlin PJ, Winston K, Swezey L et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and foodreinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003;14:583-588.
82. Verty AN, McGregor IS, Mallet PE. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 2004;354:217-220. (Pubitemid 38045348)
83. Thiemann G, Watt CA, Ledent C, Molleman A, Hasenöhrl RU. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behav Brain Res 2009;200:60-67.
84. De Vries TJ, Shaham Y, Homberg JR et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001;7:1151-1154. (Pubitemid 33010025)
85. Lesscher HM, Hoogveld E, Burbach JP, van Ree JM, Gerrits MA. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. Eur Neuropsychopharmacol 2005;15:31-37. (Pubitemid 39574397)
86. Soria G, Mendizábal V, Touriño C et al. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 2005;30:1670-1680. (Pubitemid 43086024)
87. De Vries TJ, Homberg JR, Binnekade R, Raasø H, Schoffelmeer AN. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) 2003;168:164-169. (Pubitemid 36851175)
88. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)- 1-(2,4-dichlorophenyl) -4-methylpyrazole- 3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug selfadministration in rats. J Pharmacol Exp Ther 2003;306:93-102. (Pubitemid 36734361)
89. Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005;312:875-883. (Pubitemid 40293744)
90. Sañudo-Peña MC, Tsou K, Delay ER et al. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 1997;223:125-128. (Pubitemid 27112792)
91. Cheer JF, Kendall DA, Marsden CA. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl) 2000;151:25-30. (Pubitemid 30639836)
92. Chaperon F, Soubrié P, Puech AJ, Thiébot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 1998;135:324-332. (Pubitemid 28254837)
93. López HH, Webb SA, Nash S. Cannabinoid receptor antagonism increases female sexual motivation. Pharmacol Biochem Behav 2009;92:17-24.
94. Navarro M, Hernández E, Muñoz RM et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997;8:491-496. (Pubitemid 27180108)
95. Haller J, Varga B, Ledent C, Freund TF. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004;15:299-304. (Pubitemid 39062560)
96. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006;318:304-311.
97. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002;16:1395-1398. (Pubitemid 35340861)
98. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005;57:261-267. (Pubitemid 40187370)
99. Gobbi G, Bambico FR, Mangieri R et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005;102:18620-18625. (Pubitemid 43011275)
100. Adamczyk P, Golda A, McCreary AC, Filip M, Przegalinski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 2008;59:217-228. (Pubitemid 351955748)
101. Steiner MA, Marsicano G, Nestler EJ et al. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 2008;33:54-67.
102. Beyer CE, Dwyer JM, Piesla MJ et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 2010;39:148-155.
103. Greenway FL, Bray GA. Combination drugs for treating obesity. Curr Diab Rep 2010;10: 108-115.
104. Bray GA. Medications for weight reduction. Endocrinol Metab Clin North Am 2008;37: 923-942.
105. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007;67:27-55. (Pubitemid 46105086)
106. Finer N, Craddock D, Lavielle R, Keen H. Prolonged weight loss with dexfenfluramine treatment in obese patients. Diabete Metab 1987;13:598-602. (Pubitemid 18087117)
107. Ward SJ, Lefever TW, Jackson C, Tallarida RJ, Walker EA. Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J Pharmacol Exp Ther 2008;325: 567-576. (Pubitemid 351574781)
108. Tzavara ET, Davis RJ, Perry KW et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003;138:544-553. (Pubitemid 36315302)
109. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG. The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 2001;426:R3-R4. (Pubitemid 32781779)
110. Bambico FR, Katz N, Debonnel G, Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007;27:11700-11711. (Pubitemid 350006914)
111. Egashira N, Matsuda T, Koushi E et al. Delta(9)-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: involvement of cannabinoid CB(1) receptor and serotonergic system. Eur J Pharmacol 2008;589:117-121.
112. Takahashi E, Katayama M, Niimi K, Itakura C. Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. Eur J Pharmacol 2008;589:149-156.